The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Trubrexa Patch ER
Trubrexa Patch ER · CAPSAICIN .00025 g/g; LIDOCAINE .0475 g/g · Patch · Transdermal · Direct_Rx
NDC 72189-0541-11 · 2.7 g in 1 PATCH · UNAPPROVED DRUG OTHER · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Direct RxUnited Statesrelabel
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Trubrexa Patch ER (Patch)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Direct_Rx | CAPSAICIN .00025 g/g; LIDOCAINE .0475 g/g | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Trubrexa Patch ER — NDC 72189-0541-11," retrieved September 3, 2026, https://drugdashboards.com/drug/72189054111.
Free to cite with attribution — see how the data is put together.